ProQR Therapeutics II B.V.
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Apr 2036
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 10, 2027The maintenance fee for Targeted RNA editing (US 11,781,134) comes due Apr 10, 2027. Unpaid by Oct 12, 2027, it lapses early.
- 1 fee due Jun 26, 2027The maintenance fee for Chemically Modified Single-Stranded RNA-Editing Oligonucleotides (US 11,851,656) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
- 1 fee due Jul 9, 2027The maintenance fee for Nucleic Acid Molecules for Pseudouridylation (US 11,866,702) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
- 1 fee due Oct 14, 2027The maintenance fee for Oligonucleotides to treat eye disease (US 10,617,707) comes due Oct 14, 2027. Unpaid by Apr 14, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 24, 2026
- Sep 29 US 12,747,440 Antisense oligonucleotides for the treatment of Stargardt disease
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,676,737 | Targeted RNA editing In force · USPTO record | In force | USPTO record | |
| US 12,655,423 | Targeted RNA Editing In force · Low confidence | In force | Low confidence | |
| US 10,760,076 | Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion In force · USPTO record | In force | USPTO record | |
| US 10,617,707 | Oligonucleotides to treat eye disease In force · USPTO record | In force | USPTO record | |
| US 10,988,763 | Single-Stranded RNA-Editing Oligonucleotides In force · High confidence | In force | High confidence | |
| US 11,649,454 | Single-Stranded RNA-Editing Oligonucleotides In force · Low confidence | In force | Low confidence | |
| US 11,851,656 | Chemically Modified Single-Stranded RNA-Editing Oligonucleotides In force · High confidence | In force | High confidence | |
| US 12,018,257 | Single-Stranded RNA-Editing Oligonucleotides In force · High confidence | In force | High confidence | |
| US 12,203,072 | Chemically Modified Single-Stranded RNA-Editing Oligonucleotides In force · High confidence | In force | High confidence | |
| US 12,545,911 | Single-Stranded RNA-Editing Oligonucleotides In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 18: 8 patents in force now held by others · 5 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
6 pending · 14 no status recorded